Cyclopharm Ltd (ASX: CYC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cyclopharm Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cyclopharm Ltd (ASX: CYC)
Latest News
Healthcare Shares
2 ASX healthcare shares rocketing over 16% on Big US news
Healthcare Shares
Bell Potter names the best ASX healthcare stocks to buy in FY25
Share Market News
ASX shares vs. property: The opportunities in 2024
Share Gainers
Why CSL, Cyclopharm, Dicker Data, and Fletcher Building shares are pushing higher
Share Gainers
Can you guess the top 3 performing All Ordinaries shares in the first week of trade?
Share Gainers
Cyclopharm (ASX:CYC) share price jumps on trading update
Healthcare Shares
Why the Cyclopharm (ASX:CYC) share price is crashing 42% lower
Healthcare Shares
Why is the Cyclopharm (ASX:CYC) share price down today?
Share Market News
Why the Cyclopharm (ASX:CYC) share price popped 6% today
Share Market News
Why the Cyclopharma (ASX:CYC) share price surged to record high today
Speculative
Cyclopharm share price rockets 22% higher on FDA application approval
⏸️ Investing
3 speculative micro-cap shares that could make you a fortune
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
01 Sep 2023 | $0.0050 | 0.00% | Interim | 11 Sep 2023 |
27 Mar 2023 | $0.0050 | 0.00% | Final | 04 Apr 2023 |
02 Sep 2022 | $0.0050 | 0.00% | Interim | 12 Sep 2022 |
04 Apr 2022 | $0.0050 | 0.00% | Final | 12 Apr 2022 |
03 Sep 2021 | $0.0050 | 0.00% | Interim | 13 Sep 2021 |
01 Apr 2021 | $0.0050 | 0.00% | Final | 13 Apr 2021 |
04 Sep 2020 | $0.0050 | 0.00% | Interim | 14 Sep 2020 |
30 Mar 2020 | $0.0050 | 0.00% | Final | 07 Apr 2020 |
06 Sep 2019 | $0.0050 | 0.00% | Interim | 16 Sep 2019 |
05 Apr 2019 | $0.0050 | 0.00% | Final | 15 Apr 2019 |
07 Sep 2018 | $0.0050 | 0.00% | Interim | 17 Sep 2018 |
06 Apr 2018 | $0.0050 | 0.00% | Final | 16 Apr 2018 |
01 Sep 2017 | $0.0000 | 0.00% | Interim | 11 Sep 2017 |
31 Mar 2017 | $0.0050 | 0.00% | Final | 10 Apr 2017 |
02 Sep 2016 | $0.0050 | 46.00% | Interim | 12 Sep 2016 |
11 Apr 2016 | $0.0050 | 100.00% | Interim | 19 Apr 2016 |
CYC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Cyclopharm Ltd
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals tobe used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
CYC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Nov 2024 | $1.46 | $0.05 | 3.56% | 11,684 | $1.41 | $1.46 | $1.41 |
31 Oct 2024 | $1.41 | $-0.10 | -6.64% | 59,161 | $1.50 | $1.51 | $1.41 |
30 Oct 2024 | $1.51 | $-0.01 | -0.66% | 33,905 | $1.51 | $1.52 | $1.47 |
29 Oct 2024 | $1.51 | $-0.01 | -0.66% | 8,217 | $1.55 | $1.55 | $1.51 |
28 Oct 2024 | $1.53 | $0.01 | 0.66% | 501,037 | $1.54 | $1.54 | $1.53 |
25 Oct 2024 | $1.52 | $-0.04 | -2.58% | 3,555 | $1.55 | $1.55 | $1.52 |
24 Oct 2024 | $1.55 | $-0.05 | -3.13% | 3,962 | $1.57 | $1.57 | $1.55 |
23 Oct 2024 | $1.60 | $0.03 | 1.90% | 18,690 | $1.60 | $1.63 | $1.56 |
22 Oct 2024 | $1.58 | $-0.02 | -1.26% | 5,485 | $1.60 | $1.60 | $1.58 |
21 Oct 2024 | $1.59 | $0.02 | 1.27% | 12,217 | $1.60 | $1.60 | $1.58 |
18 Oct 2024 | $1.57 | $0.01 | 0.64% | 5,938 | $1.57 | $1.57 | $1.57 |
17 Oct 2024 | $1.57 | $-0.04 | -2.50% | 30,172 | $1.60 | $1.70 | $1.56 |
16 Oct 2024 | $1.60 | $0.03 | 1.91% | 58,672 | $1.63 | $1.67 | $1.56 |
15 Oct 2024 | $1.57 | $0.00 | 0.00% | 17,221 | $1.57 | $1.57 | $1.54 |
14 Oct 2024 | $1.57 | $-0.14 | -8.19% | 18,665 | $1.72 | $1.72 | $1.57 |
11 Oct 2024 | $1.71 | $0.01 | 0.59% | 1,590 | $1.72 | $1.72 | $1.71 |
10 Oct 2024 | $1.70 | $0.00 | 0.00% | 24,804 | $1.72 | $1.72 | $1.70 |
09 Oct 2024 | $1.70 | $-0.05 | -2.87% | 21,835 | $1.75 | $1.75 | $1.70 |
08 Oct 2024 | $1.75 | $0.05 | 2.94% | 6,916 | $1.70 | $1.75 | $1.70 |
07 Oct 2024 | $1.70 | $-0.05 | -2.86% | 66,190 | $1.75 | $1.75 | $1.68 |
04 Oct 2024 | $1.75 | $0.11 | 6.71% | 42,978 | $1.65 | $1.75 | $1.64 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
30 Sep 2024 | John Wigglesworth | Buy | 33,000 | $50,752 |
On-market trade.
|
28 Jun 2024 | Kevin Barrow | Issued | 14,084 | $20,000 |
Participation in share purchase plan.
|
28 Jun 2024 | David Heaney | Issued | 21,126 | $30,000 |
Participation in share purchase plan.
|
28 Jun 2024 | Dianne Angus | Issued | 12,323 | $17,500 |
Participation in share purchase plan.
|
03 Jun 2024 | Gregory King | Buy | 10,000 | $14,624 |
On-market trade.
|
29 May 2024 | John Wigglesworth | Buy | 20,979 | $29,430 |
On-market trade.
|
30 Nov 2023 | James McBrayer | Exercise | 200,000 | $262,000 |
Exercise of options. estimated value
|
30 Nov 2023 | James McBrayer | Buy | 200,000 | $262,000 |
Exercise of options. estimated value
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David James Heaney | Non-Executive DirectorNon-Executive Chairman | Nov 2006 |
Mr Heaney was appointed to the Cyclopharm Board on 20 November 2006 and is currently the Chairman of Cyclopharm and Chairman of the Remuneration and Board Nomination Committees. He was formerly Chairman of the Audit and Risk Committee until 28 February 2019. Mr Heaney was re appointed as acting Chairman of the Audit and Risk Committee effective 1 December 2021 until 18 February 2024. Mr Heaney has also served as a Non Executive Director of a number of ASX listed and non listed companies. Mr Heaney has more than 40 years experience in all aspects of wholesale banking and finance, gained in general management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US.
|
Ms Dianne Margaret Angus | Non-Executive Director | Aug 2021 |
Ms Angus was appointed to the Board on 10 August 2021. She is a member of the Audit and Risk Committee, Remuneration Committee and Board Nomination Committee. Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has long been involved in path to market asset development and commercialisation in these industries, notably including the clinical validation of therapeutics to create asset valuation uplift. Ms Angus has wide expertise in corporate strategy and innovative product development together with governance and compliance in listed capital markets.
|
Mr James S McBrayer | Chief Executive OfficerManaging DirectorCompany Secretary | Jun 2008 |
Mr McBrayer has been a member of the Board since 3 June 2008 at which time he accepted the role of Managing Director. Mr McBrayer serves as a member of the Board Nominations Committee. Mr McBrayer has more than 30 years experience in nuclear medicine and is a trained Nuclear Pharmacist. Mr McBrayer held the role of Managing Director at Lipa Pharmaceuticals, Australia's largest contract manufacturer of over the counter products and senior management positions with Brambles Cleanaway business and Syncor, the world's largest radioactive diagnostic and therapeutic pharmaceutical provider.
|
Mr Kevin Michael John Barrow | Non-Executive Director | Sep 2022 |
Mr Barrow was appointed to the Board on 1 September 2022. He is a member of the Audit and Risk Committee, Remuneration Committee and Board Nomination Committee. Mr Barrow holds a Master of Science (with 1st Class Honours) from Waikato University, New Zealand. He obtained an MBA from the Macquarie Graduate School of Management, Sydney, Australia and is a graduate of the Australian Institute of Company Directors and an Adjunct Fellow at Macquarie University. He brings to the Cyclopharm board more than 20 years of experience in the healthcare industry, which includes numerous governance and senior executive roles.
|
Mr Gregory George King | Non-Executive Director | Sep 2022 |
Dr King is Professor of Respiratory Medicine at the Northern and Central Clinical Schools of the University of Sydney. He is also the Staff Specialist in the Department of Respiratory Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research. In addition, Dr. King supervises PhD and other postgraduate students at the University of Sydney.
|
Mr John Wigglesworth | Non-Executive Director | Feb 2024 |
Mr Wigglesworth brings with him 37 years of professional experience, including nearly 25 years as a Partner at KPMG. His background as a Chartered Accountant and Company Director, coupled with his industry experience. Mr Wigglesworths career include a company director having held several previous Board positions over the past decade including Atlas Arteria Limited (ASX:ALX) and also in public sector health entities, While at KPMG John advised and supported many Australian and international multinational companies during periods of international growth., Held various KPMG leadership positions including serving as a member of the Audit Leadership Group and National leader of KPMG Audits Retention & Conversion function, managing proposals, client relationship management, and global management groups/committees, Expertise in ASX listing readiness, IPOs, and business transition, working closely with companies navigating the challenges of transitioning to a listed entity, Financial reporting and market communications, on ASX and regulatory reporting along with financial reporting matters. He has experience in risk management, including Cyber, and serving as Chairman of the Audit & Risk Committee at both Atlas Arteria Limited and Macquarie University.
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Anglo Australian Christian and Charitable Fund | 13,211,332 | 14.04% |
Barings Acceptance Limited | 11,444,962 | 12.16% |
HSBC Custody Nominees (Australia) Limited A/c 2 | 9,754,594 | 10.37% |
National Nominees Limited | 9,706,764 | 10.32% |
Chemical Overseas Limited | 8,005,769 | 8.51% |
CVC Limited | 6,644,758 | 7.06% |
Citicorp Nominees Pty Limited | 3,893,748 | 4.14% |
McBrayer Reid Investments Pty Ltd LTIP 6 | 1,721,554 | 1.83% |
Chemical Overseas Limited II | 1,182,239 | 1.26% |
UBS Nominees Pty Ltd | 1,111,535 | 1.18% |
Mr James McBrayer | 1,061,728 | 1.13% |
Phillips River Pty Ltd <GAT A/c> | 1,038,914 | 1.10% |
Lloyds & Casanove Investment Partners Ltd | 987,503 | 1.05% |
Mr James McBrayer II | 861,728 | 0.92% |
South Seas Holdings Pty Limited | 686,538 | 0.73% |
City & Westminster Limited | 556,327 | 0.59% |
Mathew Farag <LTIP Account Holding 4> | 500,000 | 0.53% |
McBrayer Reid Investments Pty Limited | 500,000 | 0.53% |
Marayong Nicholas Pty Ltd | 431,758 | 0.46% |
Marayong Nicholas Pty Ltd II | 425,000 | 0.45% |